Phase 1 N=19 Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=22 Effects of Drugs on Responses to Brain and Emotional Processes
Autism Spectrum Disorder · Healthy
Primary: Change in Responses to Affective Touch — 3.01; 4.06 units on a scale
N/A N=28 Individual Differences in the Response to Drugs
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Early Phase 1 N=30 Behavior Brain Responses
Alcohol Drinking · Drinking Behavior · Physiological Effects of Drugs
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Across Sessions…
Phase 1 N=11 The Behavioral Effects of Opioids and Alcohol
Opioid Use · Alcohol Drinking
Primary: Peak Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 12.9; 47.1; 49.9; 54.8 score on a scale
Early Phase 1 N=138 Drugs Brain and Behavior (DDP)
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Phase 1 N=10 Marijuana Effects on Simulated Driving Performance
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
Phase 4 N=44 Conditioned Pharmacotherapeutic Effects in Hypertension
Hypertension
Primary: Mean Systolic Blood Pressure — 151.59; 152.64; 155.42; 151.74 mmHg
Phase 1 N=36 Effect of Stimulant Drugs on Social Perception
Healthy · MDMA ('Ecstasy')
Primary: Responses to Affective Touch — -1.24; 0.12; 0.19; 0.25 units on a scale
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Phase 4 N=20 Physiological Effects of Nitrous Oxide on Anaesthesia
Anesthesia
Primary: Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes) — 0.32; 0.44; 0.23; 0.32 ratio
Phase 4 N=30 Cardiovascular Effects of Adderall in Healthy Adults.
Hemodynamics · Cardiovascular System
Primary: Systolic Blood Pressure — 116; 116; 126; 115 mmHg
Phase 4 N=10 The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
Healthy
Primary: Change in Brain Nicotinamide Adenine Dinucleotide Metabolites NAD+/NADH — -0.79 ratio
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
Phase 4 N=133 Interactions Between Drug Effects and Environments II
Substance-Related Disorders
Primary: Change in Time Spent in Drug-paired Room — 24.5; 6.2 seconds
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Phase 2 N=10 Genetic Effects on Dopamine Response to an Opiate
Polymorphism-Genetic · Pain · Addiction
Primary: 11C Raclopride Binding Potential in Caudate — 3.25; 3.45 mCi/ml
N/A N=65 Effects of MDMA on Social and Emotional Processing
Drug Addiction
Primary: Emotional Recognition (MDMA) — 55.9 percent intensity
N/A N=10 Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)
Conscious Sedation · Deep Sedation · Critical Care
Primary: Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus…
N/A N=20 The Psychophysiological Effect of Simulated and Terrestrial Altitude
Hypoxia · Altitude Hypoxia · Altitude Sickness
Primary: Oxygenation of the Brain — 54.6; 54.3; 59.4; 55.4 percentage of oxygen saturation
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 2 N=13 Persisting Effects of Psilocybin
Healthy
Primary: Amygdala Response to Stimuli in the Emotion Recognition Test — 0.835; -0.759; 0.619; 0.503 BOLD percent signal change
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
Phase 2 N=100 Physiologic Effects of Steroids in Cardiac Arrest
Inhospital Cardiac Arrest
Primary: Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible). — 78.4; 75.1 mmHg…
Phase 4 N=60 Characterizing and Predicting Drug Effects on Cognition
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 4 N=60 Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Anxiety Disorder
Primary: Magnitude of Startle Reflex During Safe Condition — 42.2880893; 42.39801; 43.61243; 44.1886408 millivolts (mV)
Early Phase 1 N=60 Individual Differences in Drug Response
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale